logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
N

Nobuhiro Shibata

Kansai Medical University
H指数:14
被引数:1,528

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)

随机化、多中心II期研究：贝伐珠单抗和紫杉醇诱导后使用阿替利珠单抗和nab-紫杉醇治疗PD-L1阳性转移性三阴性乳腺癌患者的方案（INDUCE试验[JBCRG-M10]）

BMJ Open
IF2.3
2026-05-130
PRE
Ozaki, Yukinori; Koyama, Shohei; Morita, Satoshi; Miyashita, Minoru; Tokuda, Emi; Shimoi, Tatsunori; Fukuoka, Megumi; Masuda, Hiroko; Takano, Yuko; Shibata, Nobuhiro; Yoshinami, Tetsuhiro; Murakami, Akari; Tamaki, Kentaro; Ishiguro, Hiroshi; Saji, Shigehira; Miwa, Asako; Matsunaga, Junko; Zheng, Yue; Nishikawa, Hiroyoshi; Masuda, Norikazu
Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study

奥氮平预防接受剂量密集型AC方案（联合节俭糖皮质激素方案）治疗的乳腺癌患者化疗所致延迟性恶心呕吐的疗效：一项单中心试点研究

BMC Cancer
IF3.4
2026-04-060
OAAI
Manami Tada; Yuichiro Kikawa; Nobuhiro Shibata; Chie Hirai; Hirotsugu Yanai; Masahiro Takada; Tomoharu Sugie
Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes

真实世界中免疫检查点抑制剂在HPV相关和HPV非相关亚型晚期宫颈癌中的多中心研究

International Journal of Clinical Oncology
IF2.8
2025-11-260
PRE
Kazuhiro Ko; Mayu Fukuda; Koji Yamanoi; Nobutaka Hayashi; Hisateru Yasui; Takuma Hayashi; Yoshihiro Yakushijin; Takehiko Tsumura; Atsushi Shirakawa; Chiho Nakashima; Yoshinori Imamura; Chikako Yamauchi; Toshio Shimizu; Takahito Ashihara; Nobuhiro Shibata; Takeshi Kotake; Aya Toyofuku; Taito Miyamoto; Rin Mizuno; Mana Taki; Ryusuke Murakami; Satoshi Morita; Manabu Muto; Masaki Mandai
Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab

紫杉类药物联合ramucirumab治疗化疗联合nivolumab后进展的晚期胃癌的疗效与安全性

Scientific Reports
IF3.9
2025-08-070
OA
Toshihiko Matsumoto; Tatsuki Ikoma; Chinatsu Makiyama; Tomoyo Yasuda; Shogen Boku; Akio Nakasya; Nobuhiro Shibata; Hiroki Nagai; Takao Tsuduki; Yusuke Matsumoto; Hisateru Yasui; Reiji Higashi; Akitoshi Sasamoto; Hironaga Satake; Kentaro Inoue; Masashi Kanai; Makoto Yamasaki
First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study

日本胃癌或胃食管结合部腺癌患者的一线帕博利珠单抗联合化疗：KEYNOTE-859 III期研究的亚组分析

international journal of oncology
IF2.8
2025-08-010
PRE
Hisateru Yasui; Masaki Aizawa; Kensei Yamaguchi; Akihito Kawazoe; Hiroki Hara; Masahiro Tsuda; Hirokazu Shoji; Naotoshi Sugimoto; Nobuhiro Shibata; Kenji Amagai; Yasuhiro Choda; Shiro Iwagami; Taito Esaki; Shigenori Kadowaki; Shinichi Shiratori; Shirong Han; Sonal Bordia; Kohei Shitara
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor–positive, HER2‑negative advanced or metastatic breast cancer

更正：来自日本的真实世界证据显示，在接受CDK4/6抑制剂联合内分泌疗法作为一线或二线治疗激素受体阳性、HER2阴性晚期或转移性乳腺癌患者的生存结局及治疗顺序方面的数据。

Breast Cancer
IF2.9
2025-06-230
OAAI
Tetsuhiro Yoshinami; Yuko Takano; Yukinori Ozaki; Yukiko Kajiwara; Mitsugu Yamamoto; Ken-ichi Watanabe; Masami Tsukabe; Fumie Fujisawa; Shigenori E. Nagai; Nobuhiro Shibata; Chiya Oshiro; Hiroko Bando; Nobuyuki Tsunoda; Kazuhiko Yamagami; Kei Koizumi; Masahiro Takada; Naoko Toriguchi; Nobuyuki Sekine; Tsutomu Kawaguchi; Shigehira Saji; Yasuaki Sagara; Satoshi Morita; Norikazu Masuda
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

来自日本的真实世界证据，关于接受CDK4/6抑制剂联合内分泌治疗作为激素受体阳性、HER2阴性晚期或转移性乳腺癌的一线或二线治疗患者的生存结局及治疗顺序。

BREAST CANCER
IF2.9
2025-05-200
OA
Yoshinami, Tetsuhiro; Takano, Yuko; Ozaki, Yukinori; Kajiwara, Yukiko; Yamamoto, Mitsugu; Watanabe, Ken-ichi; Tsukabe, Masami; Fujisawa, Fumie; Nagai, Shigenori E.; Shibata, Nobuhiro; Oshiro, Chiya; Bando, Hiroko; Tsunoda, Nobuyuki; Yamagami, Kazuhiko; Koizumi, Kei; Takada, Masahiro; Toriguchi, Naoko; Sekine, Nobuyuki; Kawaguchi, Tsutomu; Saji, Shigehira; Sagara, Yasuaki; Morita, Satoshi; Masuda, Norikazu
Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal Adenocarcinoma

根据糖类抗原19-9水平改变化疗方案的新辅助治疗可切除/临界可切除胰腺导管腺癌

ANNALS OF SURGICAL ONCOLOGY
IF3.5
2024-10-210
PRE
Hashimoto, Daisuke; Satoi, Sohei; Yamaki, So; Nakayama, Shinji; Shibata, Nobuhiro; Matsumura, Kazuki; Miyazaki, Hidetaka; Matsui, Yuki; Tsybulskyi, Denys; Sang, Nguyen Thanh; Ikeura, Tsukasa; Kanai, Masashi; Sekimoto, Mitsugu
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) (Aug, 10.1007/s12282-024-01614-1, 2024)
BREAST CANCER
IF2.9
2024-09-200
OAAI
Nakayama, Takahiro; Niikura, Naoki; Yamanaka, Takashi; Yamamoto, Mitsugu; Matsuura, Kazuo; Inoue, Kenichi; Takahara, Sachiko; Nomura, Hironori; Kita, Shosuke; Yamaguchi, Miki; Aruga, Tomoyuki; Shibata, Nobuhiro; Shimomura, Akihiko; Ozaki, Yuri; Sakai, Shuji; Takiguchi, Daisuke; Takata, Takehiko; Bastanfard, Armin; Shiosakai, Kazuhito; Tsurutani, Junji
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

曲妥珠单抗deruxtecan治疗脑和/或软脑膜转移的HER2-positive乳腺癌患者: 使用多中心回顾性研究 (roset-bm) 数据进行的更新的总生存分析

BREAST CANCER
IF2.9
2024-08-125
OAAI
Nakayama, Takahiro; Niikura, Naoki; Yamanaka, Takashi; Yamamoto, Mitsugu; Matsuura, Kazuo; Inoue, Kenichi; Takahara, Sachiko; Nomura, Hironori; Kita, Shosuke; Yamaguchi, Miki; Aruga, Tomoyuki; Shibata, Nobuhiro; Shimomura, Akihiko; Ozaki, Yuri; Sakai, Shuji; Takiguchi, Daisuke; Takata, Takehiko; Bastanfard, Armin; Shiosakai, Kazuhito; Tsurutani, Junji
A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody

紫杉醇联合两周一次的西妥昔单抗治疗先前接受铂类化疗和anti-PD-1抗体治疗的复发或转移性头颈癌患者的II期试验

ESMO OPEN
IF8.3
2024-06-014
OAAI
Koyama, T.; Kiyota, N.; Boku, S.; Imamura, Y.; Shibata, N.; Satake, H.; Tanaka, K.; Hayashi, H.; Onoe, T.; Asada, Y.; Yamazaki, T.; Nose, T.; Ohata, S.; Nagatani, Y.; Kimbara, S.; Funakoshi, Y.; Teshima, M.; Shinomiya, H.; Minami, H.
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Yamanaka, Takashi; Niikura, Naoki; Nakayama, Takahiro; Yamamoto, Mitsugu; Matsuura, Kazuo; Inoue, Kenichi; Takahara, Sachiko; Nomura, Hironori; Kita, Shosuke; Yamaguchi, Miki; Aruga, Tomoyuki; Shibata, Nobuhiro; Shimomura, Akihiko; Ozaki, Yuri; Sakai, Shuji; Takiguchi, Daisuke; Takata, Takehiko; Bastanfard, Armin; Shiosakai, Kazuhito; Tsurutani, Junji
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
NPJ BREAST CANCER
IF7.6
2023-10-1131
OAAI
Niikura, Naoki; Yamanaka, Takashi; Nomura, Hironori; Shiraishi, Kazuhiro; Kusama, Hiroki; Yamamoto, Mitsugu; Matsuura, Kazuo; Inoue, Kenichi; Takahara, Sachiko; Kita, Shosuke; Yamaguchi, Miki; Aruga, Tomoyuki; Shibata, Nobuhiro; Shimomura, Akihiko; Ozaki, Yuri; Sakai, Shuji; Kiga, Yoko; Izutani, Tadahiro; Shiosakai, Kazuhito; Tsurutani, Junji
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: A multicenter retrospective study (ROSET-BM study)
CANCER RESEARCH
IF16.6
2023-03-017
PRE
Yamanaka, Takashi; Niikura, Naoki; Nomura, Hironori; Kusama, Hiroki; Yamamoto, Mitsugu; Matsuura, Kazuo; Inoue, Kenichi; Takahara, Sachiko; Kita, Shosuke; Yamaguchi, Miki; Aruga, Tomoyuki; Shibata, Nobuhiro; Shimomura, Akihiko; Ozaki, Yuri; Shiraishi, Kazuhiro; Sakai, Shuji; Kiga, Yoko; Izutani, Tadahiro; Shiosakai, Kazuhito; Tsurutani, Junji

研究方向

暂未获取到该数据
S
Shogen Boku
H 指数:10论文数:129被引数:451
M
M. Yamamoto
H 指数:7论文数:64被引数:255
H
Hisateru Yasui
H 指数:25论文数:285被引数:5,543
H
Hironaga Satake
H 指数:24论文数:314被引数:3,558
J
Junji Tsurutani
H 指数:53论文数:366被引数:1.8万
T
Tomoyuki Aruga
H 指数:16论文数:136被引数:2,537
A
Akihiko Shimomura
H 指数:28论文数:263被引数:3,726
K
Kenichi Inoue
H 指数:50论文数:408被引数:1.5万
T
Toshihiko Matsumoto
H 指数:10论文数:116被引数:623
T
Tatsuki Ikoma
H 指数:5论文数:88被引数:122